We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE) (CASTLE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01520155
First Posted: January 27, 2012
Last Update Posted: December 23, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Henrik Fox, Johann Wolfgang Goethe University Hospitals
December 12, 2011
January 27, 2012
December 23, 2013
December 2011
December 2012   (Final data collection date for primary outcome measure)
Identification of cardiovascular risk in patients with systemic Lupus Erythematodes [ Time Frame: one year ]
Identification of cardiovascular risk in patients with systemic Lupus Erythematodes
Same as current
Complete list of historical versions of study NCT01520155 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)
CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE): Studie Zur Detektion Des kardiovaskulären Risikos in Patienten Mit Systemischem Lupus Erythematodes
The key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three groups of patients will be compared.
Key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three group of patients will be compared as followed. First group are patients with known systemic Lupus erythematodes without renal affection, second group are patients with known systemic Lupus erythematodes with renal affection and the third group are patients with a non-autoimmun chronic kidney disease
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Every participant will provide 20 ml Serum for further laboratory analysis
Non-Probability Sample
Patients with or without systemic Lupus erythematosus
Systemic Lupus Erythematosus
Not Provided
  • Systemic lupus erythematosus with renal affection
    30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
  • Systemic lupus erythematosus without renal affection
    30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
  • Non-autoimmune kidney disease
    Patients with non-systemic, non-autoimmune kidney disease
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
December 2012
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with systemic Lupus erythematosus

Exclusion Criteria:

  • Patients without systemic Lupus erythematosus
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01520155
sleffm001
No
Not Provided
Not Provided
Henrik Fox, Johann Wolfgang Goethe University Hospitals
Johann Wolfgang Goethe University Hospital
Not Provided
Study Chair: Joachim R Ehrlich, MD Frankfurt University Academic Medical Center
Johann Wolfgang Goethe University Hospital
December 2013